Cited by 60Liver Disease Diagnosis and TreatmentMitochondrial Function and PathologyLiver physiology and pathology

Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes

Open access
Gancheva, Sofiya, Kahl, Sabine, Pesta, Dominik, Mastrototaro, Lucia, Dewidar, Bedair, Strassburger, Klaus, Sabah, Ehsan, Esposito, Irene +9 more·2022·Diabetes Care

Published version of a preprint

Abstract

OBJECTIVE: Individuals with type 2 diabetes are at higher risk of progression of nonalcoholic fatty liver (steatosis) to steatohepatitis (NASH), fibrosis, and cirrhosis. The hepatic metabolism of obese individuals adapts by upregulation of mitochondrial capacity, which may be lost during the progression of steatosis. However, the role of type 2 diabetes with regard to hepatic mitochondrial function in NASH remains unclear. RESEARCH DESIGN AND METHODS: We therefore examined obese individuals with histologically proven NASH without (OBE) (n = 30; BMI 52 ± 9 kg/m2) or with type 2 diabetes (T2D) (n = 15; 51 ± 7 kg/m2) as well as healthy individuals without liver disease (CON) (n = 14; 25 ± 2 kg/m2). Insulin sensitivity was measured by hyperinsulinemic-euglycemic clamps with d-[6,6-2H2]glucose. Liver biopsies were used for assessing mitochondrial capacity by high-resolution respirometry and protein expression. RESULTS: T2D and OBE had comparable hepatic fat content, lobular inflammation, and fibrosis. Oxidative capacity in liver tissue normalized for citrate synthase activity was 59% greater in OBE than in CON, whereas T2D presented with 33% lower complex II–linked oxidative capacity than OBE and higher H2O2 production than CON. Interestingly, those with NASH and hepatic fibrosis score ≥1 had lower oxidative capacity and antioxidant defense than those without fibrosis. CONCLUSIONS: Loss of hepatic mitochondrial adaptation characterizes NASH and type 2 diabetes or hepatic fibrosis and may thereby favor accelerated disease progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc21-1758

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 47 · Cited by 60

Authors
Gancheva, S., Kahl, S., Pesta, D., Mastrototaro, L., Dewidar, B., Strassburger, K., Sabah, E., Esposito, I., Weiß, J., Sarabhai, T., Wolkersdorfer, M., Fleming, T., Nawroth, P., Zimmermann, M., Reichert, A. S., Schlensak, M., & Roden, M.
Affiliations
  • Düsseldorf University Hospital (DE)
  • Deutsches Diabetes-Zentrum e.V. (DE)
  • Tanta University (EG)
  • Krankenhaus Neuwerk "Maria von den Aposteln" (DE)
  • Institute of Pathology, Heinrich Heine University, Düsseldorf, Germany
  • Landesapotheke Salzburg, Salzburg, Austria
  • University Hospital Heidelberg (DE)
Corresponding author
Roden, Michael
Venue
Diabetes Care
Published
2022-02-03
Volume
45
Issue
4
Pages
928-937
ISSN
0149-5992 (ISSN-L)
OpenAlex
W4210676802
Cited by
60
References
47
Citations by year
2026: 12 · 2025: 17 · 2024: 13 · 2023: 14 · 2022: 4
FWCI
8.66
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • Gilead Sciences
  • Danone
  • Deutsche Forschungsgemeinschaft (SFB 1116, SFB 1116/2)
  • Bundesministerium für Gesundheit
  • Novo Nordisk
  • Servier
  • Allergan
  • European Regional Development Fund (EFRE-0400191)
  • Eurostars
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
nonalcoholic steatohepatitis, type 2 diabetes, hepatic mitochondrial function, mitochondrial oxidative capacity, liver fibrosis, oxidative stress, antioxidant defense, hepatic steatosis, obesity, insulin sensitivity, succinate dehydrogenase, hydrogen peroxide production
MeSH terms
Diabetes Mellitus, Type 2, Humans, Hydrogen Peroxide, Liver, Liver Cirrhosis, Mitochondria, Obesity, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review